Rhythm Pharmaceuticals (RYTM) Enterprise Value (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Enterprise Value data on file, last reported at -$340.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 8.31% year-over-year to -$340.6 million in Q1 2026; TTM through Mar 2026 was -$340.6 million, a 8.31% decrease from a year earlier, with the FY2025 full-year figure at -$388.9 million, down 21.33% from the prior year.
• Enterprise Value for Q1 2026 stood at -$340.6 million, up from -$388.9 million in the prior quarter.
• Over the last five years, Enterprise Value for RYTM reached as high as -$201.7 million in Q1 2024 and fell as low as -$780.1 million in Q3 2025.
• Historically, Enterprise Value has averaged -$325.9 million across 5 years, with a median of -$299.6 million in 2023.
• Across the five-year window, Enterprise Value surged 40.43% in 2022 and plunged 161.02% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$333.6 million in 2022, then rose by 17.22% to -$276.2 million in 2023, then slipped by 16.07% to -$320.6 million in 2024, then declined by 21.33% to -$388.9 million in 2025, then grew by 12.42% to -$340.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$340.6 million in Q1 2026, -$388.9 million in Q4 2025, and -$780.1 million in Q3 2025.